Tebentafusp and LDT for metastatic uveal melanoma
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have uveal melanoma that has spread to the liver, and at least one liver tumor that is 10 mm or larger on a scan.
- You have a specific genetic marker called HLA-A*0201 (a blood test will check this).
- You have not had tebentafusp before.
- You are in generally good health (ECOG score 0 or 1) and expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
This trial tests if immune cells taken from a liver tumor can be given back to fight metastatic melanoma. It is for people with stage IV uveal or cutaneous melanoma that has worsened after standard treatments.
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.